Article citationsMore>>
Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B.Y., et al. (2012) Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly(ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients with BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 372-379.
has been cited by the following article:
-
TITLE:
Current Possible Drug Therapies for Ovarian Cancer
AUTHORS:
Jungyeob Seoung, Young-Han Park, Chaechun Rhim, Sungju Kim
KEYWORDS:
Ovarian Cancer, Intraperitoneal Chemotherapy, Targeting Therapy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.13,
November
7,
2014
ABSTRACT:
Ovarian cancer is the most aggressive
gynecologic cancer of the heterogenous phenotypes. Development of the new
chemotherapeutic agents and drug delivery mode makes better outcomes for
patient treatments. Optimal cytoreductive therapy followed by molecular
targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is
a hot therapeutic concept in ovarian cancers. In our review, we will introduce
recent therapeutic advances in epithelial ovarian cancer patients.
Related Articles:
-
Eric L. Matteson, Tim Bongartz, Jay H. Ryu, Cynthia S. Crowson, Thomas E. Hartman, Paul F. Dellaripa
-
Ashish C. Suthar, Vikas G. Pai, Yogesh Kadam, Aniruddha Tongaonkar, Shailaja Kale, Atul B. Deshpande, Sharat Kolke, Snehal Tanna, Shrikant V. Deshpande, Purvi Chawla, Debjit Biswas, Somesh Sharma
-
Anatoly Boleslavovich Smulevich, Natalia Alekseevna Ilyina, Victoria Valentinovna Chitlova
-
Dávid Pintér, Júlia Lajtos, József Janszky, Norbert Kovács
-
A. Sparavigna, B. Tenconi, I. De Ponti, A. Bulgheroni, F. Scarci